綠葉製藥(02186.HK)就創新藥利斯的明多日透皮貼劑與東和藥品訂立獨家協議
格隆匯 2 月 18日丨綠葉製藥(02186.HK)發佈公吿,公司全資附屬公司Luye Pharma Switzerland AG(“綠葉瑞士”)就利斯的明多日透皮貼劑(“利斯的明多天貼劑”或“LY30410”)與Towa Pharmaceutical Co., Ltd.(“東和藥品”)在日本訂立獨家許可、開發及商業化協定。
根據協定,綠葉瑞士將授予東和藥品在日本開發和商業化利斯的明多天貼劑的獨家權利。東和藥品將在協定簽署後向綠葉瑞士支付首付款,並在利斯的明多天貼劑達成若干開發、監管及銷售里程碑時,向綠葉瑞士支付後續的里程碑付款。東和藥品還將向綠葉瑞士支付基於利斯的明多天貼劑銷售的特許權使用費。此外,利斯的明多天貼劑在日本作為新藥預計即將進入III期臨牀,東和藥品將承擔該產品在日本臨牀研究和註冊目的有關的所有成本和費用。
董事會相信,東和藥品作為一家擁有專業團隊的日本知名製藥公司,將加快利斯的明多天貼劑的研究及開發和商業化進程,以滿足日本患者的臨牀需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.